Overview
ISO/TS 20853:2026 - Biotechnology - Bioprocessing - General requirements for bacteriophage preparation for therapeutic use establishes a standardized framework for the preparation of bacteriophage products intended for human therapeutic applications. Developed by the International Organization for Standardization (ISO), this technical specification defines the minimum requirements for the processes of phage isolation, culture, characterization, quality control, and storage. With the growing interest in phage therapy as an alternative or complement to antibiotics-especially in the fight against multidrug-resistant (MDR) bacteria-this standard supports safe, effective, and high-quality phage product development for clinical practice.
Key Topics
-
Bacteriophage Isolation and Enrichment
Outlines procedures for extracting phages from diverse environmental and clinical sources, focusing on environments rich in the target host bacteria, such as hospital samples, soils, or sewage.
-
Phage Characterization and Selection
Details steps for identification, genome sequencing, and bioinformatic analysis to ensure absence of undesirable genes (e.g., virulence, drug resistance, lysogeny) in final therapeutic phage preparations.
-
Phage Amplification and Storage
Defines requirements for phage amplification methods and titre determination, as well as best practices for short- and long-term storage, maintaining high viability and traceability of phage stocks.
-
Quality Control Procedures
Specifies critical quality markers, including:
- Removal of harmful bacterial toxins (endotoxins, exotoxins)
- PFU (Plaque-Forming Unit) titration and concentration standards
- Endotoxin quantification using validated methods
- Sterility, absence of bacterial proteins and DNA contaminants
- pH verification for clinical safety and product stability
-
Documentation and Traceability
Emphasizes comprehensive record keeping at every stage, from sampling to storage, to ensure reproducibility, transparency, and regulatory compliance.
Applications
ISO/TS 20853:2026 is vital for developers, manufacturers, and researchers working in biopharmaceuticals, biotechnology, and clinical microbiology focused on phage-based therapies. Applications include:
-
Therapeutic Phage Product Manufacturing
Ensures robust quality management systems for large-scale production of clinical-grade phages, supporting regulatory approvals and consistent therapeutic efficacy.
-
Clinical Trials and Hospital Use
Standardizes the preparation and quality assessment of phage preparations deployed in clinical studies or individualized therapies targeting antibiotic-resistant infections.
-
Research and Development
Provides a baseline for academic and industrial research dedicated to phage discovery, characterization, and optimization for medical use.
-
Phage Banks and Biorepositories
Guides the establishment and maintenance of reliable phage collections by defining stringent preservation and documentation practices.
By following this standard, organizations can improve the reproducibility and global acceptance of their bacteriophage products, supporting advances in precision bio-therapeutics and the growing field of phage therapy.
Related Standards
For comprehensive bacteriophage preparation and quality assessment, ISO/TS 20853:2026 refers to or aligns with several other key international standards, including:
- ISO 29701:2010 – Nanotechnologies - Endotoxin test on nanomaterial samples for in vitro systems
- ISO 10705-3:2003 – Water quality - Detection and enumeration of bacteriophages
- ISO 21702:2019 – Measurement of antiviral activity on plastics and other non-porous surfaces
- ISO 11737-3:2023 – Sterilization of medical devices - Tests of sterility
- ISO 10993-11:2017 – Biological evaluation of medical devices - Tests for systemic toxicity
- ISO 20397-2:2021 – Biotechnology - Data processing and bioinformatics for genome sequencing
- USP <71> / EP 2.6.1 – Sterility tests for pharmaceuticals
Adherence to ISO/TS 20853:2026 and these related standards ensures a globally harmonized approach to the safe and effective development of bacteriophage therapies, supporting quality, safety, and innovation in biotechnology and bioprocessing.